Knowledge About Respiratory Syncytial Virus and Acceptance of Infant Monoclonal Antibody for RSV and RSV Vaccination During Pregnancy

作者：Jennifer L. Kuntz, Tara M Babu, Leora R. Feldstein, Janet A. Englund, Collrane J Frivold, Holly C. Groom, Ning Smith, Alexandra Varga, Sarah N. Cox, Stephen P. Fortmann, Richard A. Mularski, Mark A. Schmidt, Ana A. Weil, Cassandra Boisvert, Madison R Hollcroft, Tara L. Hatchie, Natalie Lo, Melissa P. MacMillan, Sacha Reich, Neil Yetz, Helen Y. Chu, Allison L. Naleway · 发表于：The Pediatric Infectious Disease Journal · 年份：2025 · DOI：10.1097/inf.0000000000004566 · 被引用次数：9 · 研究领域：Respiratory viral infections research、COVID-19 Impact on Reproduction、COVID-19 Clinical Research Studies

BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States (US). RSV immunization, in the form of a monoclonal antibody (mAb) for infants and vaccines for pregnant people, may reduce infant RSV risk. METHODS: In April and May 2023, we surveyed adults with children in Oregon and Washington about the likelihood to accept infant mAb and maternal RSV vaccine and RSV awareness. We used multivariable logistic regression to identify predictors of self-reported likelihood of accepting RSV immunization. RESULTS: Among 1082 respondents, 68% and 70% responded they would very likely accept infant mAb or maternal RSV vaccine, respectively. Respondents had lower odds of accepting infant mAb (OR: 0.10, 95% CI: 0.07-0.15) and maternal RSV vaccine (OR: 0.16, 95% CI: 0.12-0.23) if they were somewhat or very concerned about side effects. Respondents had higher odds of accepting infant mAb if they received an influenza vaccination (OR: 3.79, 95% CI: 1.88-7.63). Respondents had higher odds of accepting maternal vaccine if they had an advanced degree (OR: 1.70, 95% CI: 1.06-2.73), had received an influenza vaccination (OR: 3.62, 95% CI: 1.80-7.25), or were aware of RSV before our survey (OR: 2.03, 95% CI: 1.03-4.01). CONCLUSION: Most respondents reported that they would likely accept RSV mAb for their infant or an RSV vaccine during pregnancy. Concerns about side effects lowered the odds of accepting immunization, however, nearly one-ha...